Ascendis Pharma A/S (ASND) Rose on Positive Trial Results

On March 21, 2024, Ascendis Pharma A/S (NASDAQ:ASND) stock closed at $146.19 per share. One-month return of ... positive results from its Phase 3 trial to treat adult growth hormone deficiency.” ... Read More

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label ... Forward-Looking Statements This press ... Read More

Forbes Press Releases

In this section, you’ll find the latest Forbes press releases and news announcements ... the 2024 Forbes list of Malaysia’s 50 Richest rose by a modest 2% to US$83.4 billion this year. Read More

Ascendis Pharma A/S ADR

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ... Read More

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

Ascendis Pharma ASND has outperformed the market over ... price of $146.29 for ASND at the time of writing. Finally -- what's the point of all this? The key insight to take from this article ... Read More

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

The open-label Phase 2 extension portion of the trial ... s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press ... Read More

Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

Innate Pharma S.A. is a global, clinical-stage biotechnology ... research and development for the benefit of patients. This press release and the information contained herein do not constitute ... Read More

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

IGC-AD1 is currently undergoing a Phase 2 clinical trial ... This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s ... Read More

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification ... Various statements in this press release are “forward-looking statements ... Read More